Cybin announces publication of research manuscript in the journal of medicinal chemistry

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that its research manuscript, entitled “synthesis and structure-activity relationships of 2,5-dimethoxy-4-substituted phenethylamines and the discovery of cyb210010: a potent, orally bioavailable and long-a.
CYBN Ratings Summary
CYBN Quant Ranking